5w9h: Difference between revisions
m Protected "5w9h" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='5w9h' size='340' side='right' caption='[[5w9h]], [[Resolution|resolution]] 4.00Å' scene=''> | <StructureSection load='5w9h' size='340' side='right' caption='[[5w9h]], [[Resolution|resolution]] 4.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5w9h]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5W9H OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5W9H FirstGlance]. <br> | <table><tr><td colspan='2'>[[5w9h]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice] and [http://en.wikipedia.org/wiki/Mers Mers]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5W9H OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5W9H FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5w9h FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5w9h OCA], [http://pdbe.org/5w9h PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5w9h RCSB], [http://www.ebi.ac.uk/pdbsum/5w9h PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5w9h ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5w9h FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5w9h OCA], [http://pdbe.org/5w9h PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5w9h RCSB], [http://www.ebi.ac.uk/pdbsum/5w9h PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5w9h ProSAT]</span></td></tr> | ||
| Line 20: | Line 20: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Lk3 transgenic mice]] | |||
[[Category: Mers]] | |||
[[Category: Pallesen, J]] | [[Category: Pallesen, J]] | ||
[[Category: Ward, A B]] | [[Category: Ward, A B]] | ||
Revision as of 13:26, 8 November 2017
MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
Structural highlights
Publication Abstract from PubMedMiddle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of approximately 36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.,Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS Proc Natl Acad Sci U S A. 2017 Aug 14. pii: 201707304. doi:, 10.1073/pnas.1707304114. PMID:28807998[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||